Navigation Links
IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Date:11/2/2007

ease (SD)) with duration of

response ranging from 7.2 to 29.7 months.

o To date, none of the patients who had an objective response by

RECIST have relapsed.

o The survival rate at 12 months is 67% and 18 patients are still

alive

o Progression Free Survival (PFS) from apheresis is 4.8 months

(95% CI, 3.94-5.72).

-- Assessment of pathological response in 2 patients (1 PR, 1 SD) showed

no residual melanoma.

-- Immune response: 18 out of 29 evaluated patients (62%) showed a

significant increase in TAA-specific cytokine-producing cells.

o The most frequently recognized antigens after vaccination with

UVIDEM were gp100 and MAGE.

-- UVIDEM was well tolerated with only one possibly related serious

adverse event (SAE) reported (age-related macular degeneration).

"The available results of this trial are very encouraging given the difficult-to-treat patient population," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. "We are confident in the potential of this product to fulfill the unmet medical need and look forward to the completion of our Phase 2 program as well as the initiation of the Phase 3 program."

About UVIDEM

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. IDM Pharma is responsible for the clinical development, regulatory and manufacturing activities for UVIDEM. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma cGMP manufacturing facilities in Irvine, California and in Paris, France.

UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase 2 clinical trials was previously announced. Thirty-eight
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... PAUL, Minn. , July 29, 2014  EnteroMedics ... medical devices using neuroblocking technology to treat obesity, metabolic ... will host a conference call on Thursday, August 7, ... results for the second quarter ended June 30, 2014 ... Call Details The second quarter conference call ...
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... PALM BEACH, Fla., Dec. 15, 2011  China Nuvo Solar ... has recently conducted its first mobile product fair demonstration ... products.  The product fair was recently held and the ... and the Third-Party Consulting Company that has been contracted ...
... 2011  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.  Isis ... 12:00 p.m. Eastern Time to provide more detail on ... been an extremely successful year for Isis and positions ...
Cached Medicine Technology:China Nuvo Solar Energy, Inc./SurgLine Announces New Mobile Marketing Campaign 2Isis Adds Three New Drugs to Its Development Pipeline 2Isis Adds Three New Drugs to Its Development Pipeline 3Isis Adds Three New Drugs to Its Development Pipeline 4Isis Adds Three New Drugs to Its Development Pipeline 5
(Date:7/29/2014)... 29, 2014 As the Ebola outbreak in ... partners to both purchase critical emergency supplies locally, as well ... Liberia. These supplies will contain materials used to control the ... populated areas of the country. , With a large ... response to the Ebola outbreak in the region. The current ...
(Date:7/29/2014)... July 29, 2014 The Board of Governors ... & Hart LLP ’s Connie Akridge to serve ... serves as President of the Foundation. Akridge served as President ... is a partner at Holland & Hart in Las Vegas, ... regulatory/administrative matters to insurance and healthcare clients for more than ...
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... leading pediatricians have joined our network, CarePoint Health ... and Dr. Sushma Kaki. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Historically, Memorial ... the United States usually celebrated throughout that time by ... those summer days now mark the start of a ... involving teen drivers. In 2012 nearly 1.000 people ... period from Memorial Day to Labor Day. , The ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2
... 8, 2011) -- Today at the Neglected Tropical Diseases ... in Boston, the Drugs for Neglected Diseases initiative (DNDi) ... new helminth infection drug portfolio to address unmet needs ... project will assess the potential of the drug flubendazole ...
... from a new study revealed that men who smoke had ... who never smoked. Researchers also reported that men who were ... likely to need arthroplasty. Details of this study are now ... Wiley-Blackwell on behalf of the American College of Rheumatology (ACR). ...
... Contrary to popular belief, so-called hypoallergenic dogs do not have ... conclusion of a study by Henry Ford Hospital researchers who ... allergen in the home than other dogs. Hypoallergenic dogs are ... fur. The findings are to be published online this ...
... "A debt ceiling agreement must be reached in time to ... patients who rely on Medicare, Medicaid and other federal health ... American College of Physicians (ACP) told the president, vice president ... our views on enactment of legislation to increase the debt ...
... that could stop the growth of glioblastoma, a deadly form ... journal Cell , a Cell Press publication, a new ... allows them to grow and seed tumors. Importantly, normal stem ... that same dependency. "When thinking about therapeutics [targeting cancer ...
... 2011Companies that try to increase sales of their products ... imply that they support breast cancer researcha practice called ... chemicals shown to cause cancer are committing a form ... article in Environmental Justice, a peer-reviewed journal ...
Cached Medicine News:Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 2Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 3Health News:Male smokers less likely to need joint replacement surgery of hip or knee 2Health News:Study: Hypoallergenic dogs not less allergic than other dogs 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 3Health News:To combat deadly brain cancer, target the stem cells 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: